Kyverna Therapeutics KYTX 深 滬
交易中 09-20 10:37:42 美东时间
6.72
-0.200
-2.89%
華盛通- 最 高6.92
- 今 開6.92
- 成交量 4.96万股
- 最 低 6.65
- 昨 收 6.92
- 總市值 2.89亿
- 52周最高 35.06
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 6.30
- 委 比 6.28%
- 總股本 4299.75万
- 歷史最高 35.06
- 量 比 0.82
- 振 幅 3.90%
- 歷史最低 6.30
- 每 手 1
- 風險率 8.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
Kyverna Therapeutics (NASDAQ:KYTX) has announced the appointment of Warner Biddle as the Co.'s CEO and a member of its Board of Directors. Mr. Biddle succeeds Peter Maag, Ph.D., who has resigned from ...
09-16 20:16
Kyverna Therapeutics Announces Leadership Update
– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successf...
09-16 20:00
快讯 | Kyverna Therapeutics股份有限公司：H.C. Wainwright将目标价从8美元下调至7美元。
Kyverna Therapeutics Inc : H.c. Wainwright Cuts Target Price to $7 From $8
08-15 18:16
Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading higher this morning on Tuesday, some of the sto...
08-13 15:44
快讯 | Kyverna Therapeutics股份有限公司-每股亏损0.67美元
Kyverna Therapeutics Inc - Qtrly Shr Loss $0.67
08-13 04:28
快讯 | Kyverna Therapeutics提供业务更新并报告2024年第二季度财务结果。
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 F...
08-13 04:08
快讯 | Kyverna治疗股份公司获得美国FDA对Kyv-101治疗渐进性重症肌无力患者的RMAT认定。
Kyverna Therapeutics Receives U.S. FDA Rmat Designation for Kyv-101 in the Trea...
08-13 04:05
快讯 | Kyverna Therapeutics公司：JP Morgan将目标价从39美元下调至33美元。
Kyverna Therapeutics Inc : JP Morgan Cuts Target Price to $33 From $39
07-31 15:08
H.C. Wainwright starts Kyverna at neutral, says awaiting more data
H.C. Wainwright initiated coverage of Kyverna Therapeutics (NASDAQ:KYTX) with a neutral rating, stating that it was awaiting more data on the company's cell therapy KYV-101 before becoming more positi...
07-04 03:19
快讯 | Kyverna Therapeutics, Inc：H.C. Wainwright发起覆盖，评级为中性，目标价为8美元。
Kyverna Therapeutics, Inc : H.c. Wainwright Initiates Coverage WithNeutra...
07-03 18:07
